Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Bourbouloux · SciRah

Researcher profile · Semantic Scholar

E. Bourbouloux

Share profile

E. Bourbouloux — researcher profile on SciRah

h-index: 14
Works: 48
Citations: 861

Most-cited papers

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
C. Rousseau, A. Devillers, C. Sagan, L. Ferrer +15 more
2006Journal of Clinical Oncology314 citations
Semantic Scholar
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial.
C. Falandry, F. Rousseau, M. Mouret-Reynier, F. Tinquaut +16 more
2021JAMA Oncology60 citations Open access
Semantic Scholar
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial.
E. Brain, C. Mertens, V. Girre, F. Rousseau +12 more
2011Critical reviews in oncology/hematology53 citations
Semantic Scholar
Oxaliplatin‐based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients
J. Frenel, C. Leux, L. Pouplin, G. Ferron +5 more
2011Journal of Surgical Oncology51 citations
Semantic Scholar
Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma
A. Pallardy, C. Bodet-Milin, A. Oudoux, L. Campion +8 more
2010European Journal of Nuclear Medicine and Molecular Imaging44 citations
Semantic Scholar
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
P. Augereau, A. Patsouris, E. Bourbouloux, C. Gourmelon +5 more
2017Therapeutic Advances in Medical Oncology43 citations Open access
Semantic Scholar
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.
N. Isambert, M. Campone, E. Bourbouloux, M. Drouin +6 more
2010European Journal of Cancer41 citations
Semantic Scholar
Taxanes in adjuvant breast cancer setting: which standard in Europe?
M. Campone, P. Fumoleau, E. Bourbouloux, P. Kerbrat +1 more
2005Critical reviews in oncology/hematology28 citations
Semantic Scholar
EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.
C. Falandry, A. Savoye, L. Stefani, F. Tinquaut +16 more
2019Journal of Clinical Oncology27 citations
Semantic Scholar
Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.
E. Brain, A. Viansone, E. Bourbouloux, O. Rigal +16 more
2022Journal of Clinical Oncology23 citations
Semantic Scholar
NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment
N. Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, I. Luescher +7 more
2011PLoS ONE16 citations Open access
Semantic Scholar
Evaluating everolimus for the treatment of breast cancer
C. Moreau-Bachelard, M. Robert, C. Gourmelon, E. Bourbouloux +3 more
2023Expert Opinion on Pharmacotherapy15 citations
Semantic Scholar
Cognitive change in breast cancer patients up to 2 years after diagnosis.
M. Lange, Sophie Lefevre Arbogast, I. Hardy-Léger, O. Rigal +21 more
2022Journal of the National Cancer Institute15 citations Open access
Semantic Scholar
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
M. Campone, N. Isambert, E. Bourbouloux, Henri Roché +3 more
2012Cancer Chemotherapy and Pharmacology14 citations
Semantic Scholar
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors
A. Awada, M. Campone, A. Varga, P. Aftimos +5 more
2016Anti-Cancer Drugs12 citations
Semantic Scholar
Benefits versus risk profile of buparlisib for the treatment of breast cancer
A. Patsouris, P. Augereau, J. Frenel, M. Robert +5 more
2019Expert Opinion on Drug Safety11 citations
Semantic Scholar
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer
M. Robert, J. Frenel, E. Bourbouloux, Dominique Berton Rigaud +4 more
2019Expert Opinion on Drug Metabolism & Toxicology10 citations
Semantic Scholar
Lapatinib in Metastatic Breast Cancer
J. Frenel, E. Bourbouloux, D. Berton-Rigaud, S. Sadot-Lebouvier +2 more
2009Women's Health10 citations Open access
Semantic Scholar
[Cardiac dysfunction induced by trastuzumab].
M. Campone, E. Bourbouloux, P. Fumoleau
2004Bulletin du Cancer10 citations
Semantic Scholar
Pertuzumab for the treatment of breast cancer
M. Robert, J. Frenel, E. Bourbouloux, Dominique Berton Rigaud +4 more
2019Expert Review of Anticancer Therapy8 citations
Semantic Scholar
Evaluation of the safety of C-1311 administered in a phase I dose-escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumors.
N. Isambert, M. Campone, E. Bourbouloux, M. Drouin +5 more
2006Journal of Clinical Oncology8 citations
Semantic Scholar
Efficacy of buparlisib in treating breast cancer
M. Robert, J. Frenel, E. Bourbouloux, Dominique Berton Rigaud +4 more
2017Expert Opinion on Pharmacotherapy7 citations
Semantic Scholar
[French translation and adaptation of the "Return to Work Self-Efficacy' Scale - 11 items" in patients diagnosed with a cancer].
B. Porro, A. Petit, E. Bourbouloux, P. Colombat +3 more
2021Bulletin du Cancer5 citations Open access
Semantic Scholar
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
M. Robert, J. Frenel, E. Bourbouloux, D. B. Rigaud +4 more
2018Drugs5 citations
Semantic Scholar
Effect of Burden of Comorbidity on Optimal Breast Cancer Treatment in Older Adults
A. Boureau, E. Bourbouloux, F. Retornaz, G. Berrut +1 more
2012Journal of The American Geriatrics Society4 citations Open access
Semantic Scholar
Les cancers du sein HER2 : que devons-nous retenir dans notre pratique clinique quotidienne ?
M. Campone, D. Berton-Rigaud, E. Bourbouloux, Sadot Sophie +2 more
20114 citations
Semantic Scholar
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors
M. Campone, N. Isambert, E. Bourbouloux, S. Maury +3 more
2007Cancer Chemotherapy and Pharmacology4 citations
Semantic Scholar
A phase-I dose-escalation study of SR271425 administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors
P. Fumoleau, M. Campone, N. Isambert, S. Maury +6 more
20054 citations
Semantic Scholar
1680P Feasibility of home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase II study
F. J. Lobbedez, C. Lefeuvre-plesse, E. Charton, C. Helissey +12 more
2021Annals of Oncology3 citations Open access
Semantic Scholar
Phase I study of intravenous (IV) milataxel in adult patients with advanced malignant tumors.
E. Bourbouloux, M. Campone, J. Vermorken, Miguel Martín +2 more
2006Journal of Clinical Oncology3 citations
Semantic Scholar
[Cancer screening practices in elderly with dementia].
G. Chapelet, G. Berrut, E. Bourbouloux, M. Campone +2 more
2015Gériatrie et Psychologie Neuropsychiatrie du Vieillissement2 citations
Semantic Scholar
[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].
J. Frenel, O. Bally, E. Bourbouloux, D. Berton-Rigaud +3 more
2016Bulletin du Cancer1 citations
Semantic Scholar
ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?
C. Dubot, E. Bourbouloux, O. Mir, S. Kirscher +16 more
20141 citations
Semantic Scholar
Evaluation of whole body MRI for early detection of cancers in subjects with germ-line TP53 mutation (Li-Fraumeni syndrome).
O. Caron, T. Frebourg, E. Bourbouloux, V. Bonadona +12 more
20131 citations
Semantic Scholar
Abstract PD5-5: Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC)
B. Melichar, A. DeMichele, A. Adenis, E. Bourbouloux +6 more
20131 citations
Semantic Scholar
Doxorubin-based adjuvant chemotherapy for elderly patients with hormone receptors negative breast carcinoma: a French geriatric oncology group (GERICO) phase II multicentric program
M. Debled, V. Girre, C. Mertens, E. Blot +7 more
20081 citations
Semantic Scholar
Clinical impact of FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels
C. Rousseau, A. Pallardy, L. Campion, E. Bourbouloux +7 more
20071 citations
Semantic Scholar
2022-RA-1294-ESGO Chemosensitivity in vulnerable older patients is unfavorable and highly dependent on the treatment regimen: CA125 elimination rate constant K (KELIM) analysis of the GINECO-ENGOT EWOC-1 trial
O. Colomban, E. Bourbouloux, Marie-Ange Mouret-Renier, D. Lorusso +15 more
2022Ovarian cancer0 citations Open access
Semantic Scholar
125P Cognitive impairment in breast cancer patients up to 18 months after cancer treatments: The French multicentric longitudinal CANTO-Cog cohort substudy
F. J. Lobbedez, I. Hardy-Léger, S. Arbogast, O. Rigal +16 more
2021Annals of Oncology0 citations Open access
Semantic Scholar
Long-term outcomes of patients with HER2+ breast cancer with small-size residual disease (≤ypT1) in the absence of pathological response after trastuzumab-based neoadjuvant chemotherapy and without adjuvant T-DM1: A monocentric retrospective study.
L. Doucet, C. Moreau-Bachelard, C. Gourmelon, M. Robert +7 more
20200 citations
Semantic Scholar
Abstract OT3-3-02: ASTER 70s UNICANCER phase III trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?
C. Dubot, E. Bourbouloux, O. Mir, S. Kirscher +16 more
20150 citations
Semantic Scholar
Abstract OT3-1-10: ASTER 70s (UNICANCER phase III trial): Is personalized adjuvant treatment for women over 70 with luminal breast cancer the way to go?
C. Dubot, E. Bourbouloux, Y. Tazi, H. Curé +21 more
20130 citations
Semantic Scholar
Adjuvant chemotherapy for luminal breast cancer in elderly women: Feasibility of the ongoing ASTER 70S gerico UNICANCER phase III trial
E. Bourbouloux, Y. Tazi, H. Curé, J. Ferrero +8 more
20130 citations
Semantic Scholar
A personalized adjuvant treatment for women over 70 presenting with a luminal breast cancer? ASTER 70s or an ongoing phase III trial with parallel cohort by the UNICANCER GERICO and UCBG groups for an ongoing question…
E. Brain, G. Romieu, F. Rollot, J. Ferrero +14 more
20120 citations
Semantic Scholar
3621 POSTER Assessing 2-month Clinical Prognosis in Patients With Solid Tumours – Final Results of PRONOPALL Study
H. Bourgeois, S. Traore, P. Maillard, M. Marcq +6 more
20110 citations
Semantic Scholar
8038 Oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients
J. Frenel, J.-M. Classe, F. Dravet, C. Leux +2 more
20090 citations
Semantic Scholar
A multicenter phase II trial of weekly paclitaxel (wPC) and epirubicin (E) in first line metastatic breast cancer (MBC) and pronostic impact of VEGF level.
S. Abadie, O. Capitain, R. Delva, P. Maillart +13 more
20090 citations
Semantic Scholar
AP5346, a pH-dependent polymer-vectorized DACH, is safe at pharmacodynamically active doses: Results from an ongoing phase II trial in borderline potentially platinum-sensitive ovarian cancer (OC) patients.
M. Campone, A. Floquet, F. Rousseau, M. Fabbro +3 more
20070 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Campone×21
Invite
M. Campone — researcher profile on SciRah
J. Frenel×13
Invite
J. Frenel — researcher profile on SciRah
E. Brain×8
Invite
E. Brain — researcher profile on SciRah
C. Gourmelon×8
Invite
C. Gourmelon — researcher profile on SciRah

×8

Invite

P. Fumoleau — researcher profile on SciRah

Invite

O. Rigal — researcher profile on SciRah

A. Patsouris×7

Invite

A. Patsouris — researcher profile on SciRah

Invite

M. Robert — researcher profile on SciRah

Invite

E. Blot — researcher profile on SciRah

Invite

P. Augereau — researcher profile on SciRah

Invite

J. Ferrero — researcher profile on SciRah

M. Lacroix-Triki×6

Invite

M. Lacroix-Triki — researcher profile on SciRah